PremiumThe FlyCoya Therapeutics provides enrollment update of COYA 302 study Coya Therapeutics initiated with a Buy at D. Boral Capital Coya Therapeutics files to sell 1.38M shares of common stock for holders PremiumCompany AnnouncementsCoya Therapeutics Announces Leadership Change and New CEO Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results Coya Therapeutics says Phase 2 LD-1L-2 study met primary, secondary endpoints PremiumThe FlyCoya Therapeutics CEO Howard Berman to leave role, Arun Swaminathan to succeed Coya Therapeutics reports Q2 EPS (19c), consensus (31c) Coya files U.S patents for COYA 301 + GLP-1 receptor agonists